VRX Crosses Above Average Analyst Target
February 16, 2018 at 09:47 AM EST
In recent trading, shares of Valeant Pharmaceuticals International Inc (VRX) have crossed above the average analyst 12-month target price of $18.43, changing hands for $18.67/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..